Plants with neurobiological activity as potential targets for drug discovery

被引:77
|
作者
Gomes, Nelson G. M. [1 ]
Campos, Maria G. [1 ]
Orfao, Joao M. C. [1 ]
Ribeiro, Carlos A. F. [2 ]
机构
[1] Univ Coimbra, Ctr Pharmaceut Studies, Lab Pharmacognosy, Fac Pharm, Coimbra, Portugal
[2] Univ Coimbra, Inst Pharmacol & Expt Therapeut, Fac Med, Educ Unit 1, Coimbra, Portugal
来源
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | 2009年 / 33卷 / 08期
关键词
Blood brain barrier; Central nervous system; Drug targets; Natural drugs; Neurological activity; Neurological diseases; ST-JOHNS-WORT; TO-MODERATE DEPRESSION; BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; IN-VITRO; MEDICINAL-PLANTS; ESSENTIAL OIL; DOUBLE-BLIND; RAT-BRAIN; SCUTELLARIA-BAICALENSIS;
D O I
10.1016/j.pnpbp.2009.07.033
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Significant number of studies has been performed to find alternatives or treatments for diseases of the nervous forum by identifying structures with activity at the central nervous system (CNS). However most of the screenings are usually conducted on an ad hoc basis and not systematically. The initial purpose of this review was to screen plants with neurological bioactivity, in particular those that have not been fully studied and that have molecular mechanisms whose active constituents responsible for the activity remain to be identified. The second purpose was to identify potential target plants for future studies of new and alternative therapies for the treatment of neurological disorders and neurodegenerative diseases. All plants considered in this review were selected for three qualities: possible molecular requirements to act at the CNS; representative of the main classes of compounds with the referred bioactivity and the major families containing species with those compounds: and diffuse world distribution. We identified several examples of plants that have potential for further study. We have included the main families of these plants, their known molecular mechanisms involved in neurological bioactivity, and the active constituents responsible for such activity. Also included is a brief discussion about the requirements of the different compounds to reach the CNS. These requirements may be less limited than what researchers have previously thought. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:1372 / 1389
页数:18
相关论文
共 50 条
  • [31] New drug targets in psychiatry: Neurobiological considerations in the genomics era
    Harrison, Paul J.
    Mould, Arne
    Tunbridge, Elizabeth M.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2022, 139
  • [32] Drug discovery from plants
    Rao, E. Venkata
    CURRENT SCIENCE, 2007, 93 (08): : 1060 - 1060
  • [33] CAN NEUROBIOLOGICAL SUBGROUPS IN PSYCHOTIC ILLNESS ADVANTAGE DRUG DISCOVERY?
    Tamminga, Carol
    Ivleva, Elena
    Clementz, Brett
    Sweeney, John
    Pearlson, Godfrey
    Keshavan, Matcheri
    SCHIZOPHRENIA BULLETIN, 2017, 43 : S3 - S3
  • [34] Novel targets for antithrombotic drug discovery
    Nanda, N
    Phillips, DR
    BLOOD CELLS MOLECULES AND DISEASES, 2006, 36 (02) : 228 - 231
  • [35] IDBS targets biologists in drug discovery
    Fox, S
    GENETIC ENGINEERING NEWS, 1997, 17 (20): : 24 - +
  • [36] New targets for antimalarial drug discovery
    Guerra, Francisco
    Winzeler, Elizabeth
    CURRENT OPINION IN MICROBIOLOGY, 2022, 70
  • [37] New targets for antibacterial drug discovery
    Miller, K.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2006, 58 : A92 - A92
  • [38] Current targets for anticancer drug discovery
    Nam, NH
    Parang, K
    CURRENT DRUG TARGETS, 2003, 4 (02) : 159 - 179
  • [39] Enzymatic Targets in the Anticancer Drug Discovery
    Scotti, Luciana
    Scotti, Marcus T.
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2024, 25 (01) : 3 - 3
  • [40] Tyrosine kinase targets in drug discovery
    Grosios, K
    Traxler, P
    DRUGS OF THE FUTURE, 2003, 28 (07) : 679 - 697